Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer

  • End date
    Jun 1, 2023
  • participants needed
  • sponsor
    Dana-Farber Cancer Institute
Updated on 1 July 2022
acute leukemia
flow cytometry
monoclonal antibodies
measurable disease
small molecule
growth factor
karnofsky performance status
organ transplantation
stem cell infusion
bone marrow procedure
intrathecal chemotherapy
blast cells
PCR test
neutrophil count
tumor cells
blood transfusion
monoclonal antibody therapy
chemotherapy regimen
cancer treatment
solid tumor
antibody therapy
platelet transfusion
cns tumor
cns neoplasm
kidney function test
autologous hematopoietic stem cell transplant


This research study is studying a novel drug called ALRN-6924 as a possible treatment for resistant (refractory) solid tumor, brain tumor, lymphoma or leukemia.

The drugs involved in this study are:

  • ALRN-6924
  • Cytarabine (for patients with leukemia only)


This research study is a Phase I clinical trial, which tests the safety of an investigational intervention and also tries to define the appropriate dose of the investigational intervention to use for further studies. "Investigational" means that the intervention is being studied.

In this research study, the investigators are evaluating a new drug, ALRN-6924, as a potential new treatment for children with cancer.

The FDA (the U.S. Food and Drug Administration) has not approved ALRN-6924 as a treatment for any disease.

This is the first time that ALRN-6924 will be studied in children.

ALRN-6924 is a drug that blocks certain proteins in tumor cells called MDM2 and MDMX. These proteins may be important in the growth of some cancers. Laboratory experiments and results from studies with adults show that ALRN-6924 may stop tumor growth and, in some cases, may cause tumor cells to die. ALRN-6924 has been tested in adults with cancer to find out about side effects and dosing in adults.

The purposes of this study are:

  • to evaluate side effects of ALRN-6924 and to find the best dose of ALRN-6924 when used in children.
  • to determine whether this drug may have benefits against the types of cancer seen in children
  • to see how the body breaks down ALRN-6924 by measuring the amount of ALRN-6924 in the blood.

One part of the study is for children with solid tumors, lymphoma, and brain tumors (Cohorts A or B). Another part of this study is for children with leukemia (Cohort C).

Condition Leukemia, Brain Tumor, Solid Tumor, Lymphoma
Treatment cytarabine, ALRN-6924
Clinical Study IdentifierNCT03654716
SponsorDana-Farber Cancer Institute
Last Modified on1 July 2022


Yes No Not Sure

Inclusion Criteria

Age > 1 years and ≤ 21 years at time of enrollment
Karnofsky performance status ≥ 50% for patients ≥16 years of age and/or Lansky ≥ 50% for patients <16 years of age
For Cohorts A and B
Participants must have evaluable or measurable disease
Must have disease that is relapsed or refractory and for which standard curative or palliative measures do not exist or are no longer effective
For Cohort A, participants must have histologically confirmed non-CNS primary solid tumors or lymphoma based upon biopsy or surgery at initial diagnosis and/or relapse/progression. The only exception to histologic confirmation is for patients with retinoblastoma
For Cohort B, participants must have one of the following confirmed diagnoses
Diagnosis of retinoblastoma
Histologic diagnosis of hepatoblastoma and WT TP53
Diagnosis of malignant rhabdoid tumor and WT TP53. For the purposes of this study, a diagnosis of malignant rhabdoid tumor will include histologic diagnosis (CNS atypical teratoid/rhabdoid tumor, rhabdoid tumor of the kidney or rhabdoid tumor of the soft tissue) AND molecular confirmation (loss of INI1 protein staining or BRG1 protein staining by IHC, or documentation of SMARCB1 or SMARCA4 mutation or loss)
Solid tumor, CNS tumor, or lymphoma with MDM2 amplification or high-copy gain and WT TP53
Solid tumor, CNS tumor, or lymphoma with MDMX amplification or high-copy gain and WT TP53
Solid tumor, CNS tumor, or lymphoma with PPM1D amplification, high-copy gain, or PPM1D activating mutation and WT TP53
Solid tumor or lymphoma with TET2 loss or loss-of-function mutation and WT TP53
Testing for MDM2, MDMX, TP53, SMARCB1, SMARCA4, PPM1D and TET2 variants must be performed in a laboratory certified to return results for clinical purposes in order to be used to qualify a patient for Cohort B
For Cohort C
Participants must have a histologically confirmed diagnosis of relapsed or refractory AML, ALL, mixed lineage leukemia, biphenotypic leukemia, or other undifferentiated acute leukemia with one of these disease states
Refractory disease defined as: Persistent disease after at least two induction cycles; OR
Relapsed disease defined as: Second or subsequent relapse, or any relapse that is refractory to salvage chemotherapy
Subjects in Cohort C must have ≥ 5% blasts (M2 or M3 marrow) definitively identified either on a bone marrow aspirate or biopsy sample, as assessed by morphology, immunohistochemical studies, flow cytometry, karyotype, cytogenetic testing such as fluorescent in situ hybridization (FISH) or other molecular studies
Subjects must have CNS1 or CNS2 disease
Absence of inactivating TP53 alteration by Next Generation Sequencing assay or
Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy except organ function as noted below. Patients must meet the following minimum washout periods prior to enrollment
PCR-based assay in a laboratory certified to return results for clinical
Myelosuppressive chemotherapy: At least 14 days after the last dose of myelosuppressive chemotherapy (42 days for nitrosourea or mitomycin C)
Patients on Cohort C may have received any of the following medications without a
wash-out" period as long as other organ function requirements are met (methotrexate must
not be given within 48 hours of ALRN-6924 planned start)
Standard maintenance therapy [any combination of vincristine, 6-mercaptopurine
corticosteroids, and/or low-dose methotrexate (45 mg/m2/week or less)]; Hydroxyurea
Patients on any cohort may have received intrathecal chemotherapy with methotrexate
hydrocortisone and/or cytarabine (non-liposomal) without a "wash-out" period as long as
other organ function requirements are met (methotrexate must not be given within 48 hours
of ALRN-6924 planned start)
At least 14 days after local XRT (small port, including cranial radiation)
At least 90 days must have elapsed after prior TBI, craniospinal XRT or if >50%
At least 42 days must have elapsed if other substantial BM radiation
radiation of pelvis
At least 42 days must have passed since last MIBG or other radionuclide therapy
Small molecule biologic therapy: At least 7 days following the last dose of a biologic
agent. For agents with known adverse events occurring beyond 7 days, this duration
must be extended beyond the time in which adverse events are known to occur. If
extended duration is required, this should be discussed with and approved by the
overall PI
Monoclonal antibody: At least 21 days must have elapsed after the last dose of
At least 90 days must have elapsed from the date of liver transplant
Myeloid growth factors: At least 14 days following the last dose of long-acting growth
All organ function requirements are met
factor (e.g. Neulasta) or 7 days following short-acting growth factor
Autologous hematopoietic stem cell transplant and stem cell boost: Patients must be at
least 60 days from day 0 of an autologous stem cell transplant or stem cell boost
Participants must have normal organ function as defined below
Allogeneic hematopoietic stem cell transplant or cellular therapies (including CAR-T
cells): The patient must have no evidence of graft versus host diseaseand at least 90
days must have elapsed after allogeneic stem cell infusion. At least 42 days must have
elapsed after last dose of other cellular therapy
Solid Organ Transplantation: Patients with hepatoblastoma treated with liver
transplantation will be eligible to enroll if they meet all of the following
Not known to be refractory to red cell and/or platelet transfusions
Bone Marrow Function for Subjects in Cohorts C with Acute Leukemia
No clinical or radiographic evidence of rejection since the date of transplant
Hepatic Function
Major Surgery: At least 2 weeks from prior major surgical procedure. Note: Biopsy, CNS
shunt placement/revision, and central line placement/removal are not considered major
Serum albumin > 2 g/dL
MDM2 inhibitors: Patients for Cohorts A and C may have received prior MDM2 inhibitor
Renal Function
therapy. Patients in Cohort B must not have received prior MDM2 inhibitor therapy
A serum creatinine within protocol limits based on age/sex. OR
Patients in all cohorts must not have received dual MDM2/MDMX inhibition
Adequate Cardiac Function: QTc < 480 msec
Bone Marrow Function for Subjects in Cohorts A and B without Bone Marrow Involvement
by Disease
Absolute neutrophil count ≥1,000 /uL
Platelets ≥75,000 /uL and transfusion independent, defined as not receiving a
platelet transfusion for at least 5 days prior to CBC documenting eligibility
Hematologic Requirements for Subjects in Cohorts A and B with Bone Marrow Involvement
by Disease
Absolute neutrophil count ≥750 /uL
Platelets ≥50,000 /uL (may receive platelet transfusions)
--Not known to be refractory to red cell and/or platelet transfusions
Total bilirubin ≤ 1.5 x upper limit of normal for age except for patients with
known Gilbert syndrome who may enroll using direct bilirubin ≤ 1.5 x upper limit
of normal for age as bilirubin criterion
ALT (SGPT) ≤ 3 x upper limit of normal (135 U/L). For the purpose of this study
the ULN for ALT is 45 U/L. Patients with acute leukemia AND leukemic infiltration
of the liver may enroll to Cohort C if ALT < grade 2 and total bilirubin meets
above requirement
Creatinine clearance ≥ 60 mL/min/1.73 m2 for participants with creatinine levels
greater than the above age/sex maximum allowed values
For patients with CNS tumors (primary or metastatic), any baseline neurologic deficits
(including seizure) must be stable for at least one week prior to study enrollment
Patients with CNS tumors receiving corticosteroids must be on a stable or decreasing
dose at time of study entry
Ability to understand and/or the willingness of the patient (or parent or legally
authorized representative, if minor) to provide informed consent, using an
institutionally approved informed consent procedure
Participants of child-bearing or child-fathering potential must agree to use adequate
contraception (hormonal birth control; intrauterine device; double barrier method; or
total abstinence) throughout their participation, including up until 30 days after
last dose of ALRN-6924

Exclusion Criteria

Patients receiving medications within 48 hours of enrollment that are primarily
cleared by organic anion transporter polypeptide [OATP] members OATP1B1 and OATP1B3
Pregnant participants will not be entered on this study given that the effects of
ALRN-6924 on the developing human fetus are unknown
Breastfeeding mothers are not eligible, because there is an unknown risk for adverse
events in nursing infants secondary to treatment of the mother with ALRN-6924
History of allergic reactions attributed to compounds of similar chemical or biologic
composition to ALRN-6924
Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements
Patients with a known history of HIV, hepatitis B, and/or hepatitis C (testing not
required as part of screening)
Patients with a known personal history of angioedema or known family history of
hereditary angioedema
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note